Throughout the last three months, 7 analysts have evaluated Vir Biotechnology VIR, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ...
a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline. Eighty-four biopharmaceuticals are now in general medical use (see Table 1).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback